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Abstract:  Native chemical ligation (NCL) is a method used to synthesize a covalent bond 
between two proteins.  The method has been extensively used to react a C-terminal thioester on 
one protein with an N-terminal cysteine residue on another protein.  Our strategy deviates from 
this usual method by incorporating a cysteine containing analogue of pyrrolysine (PCA) into any 
site on a recombinant protein.  My work uses NCL to conjugate Small Ubiquitin like Modifier 
(SUMO) to Hypoxia Inducible Factor -1α (HIF-1α) prelabeled with PCA. 
HIF-1α is a transcription factor that is known to generate a protective response during 
hypoxia, a common symptom of stroke in which there are depleted oxygen levels in tissues.  
Furthermore, during hypoxia, SUMO is conjugated to HIF-1α at Lys391 and Lys477.  An in vitro 
preparation of SUMOylated HIF-1α is desired because of two challenges in isolating the protein 
from in vivo preparations; first, HIF-1α is rapidly degraded in normal respiring tissues and 
second, deconjugating enzymes cleave SUMO away once the function of the SUMOylated form 
is mediated in the cell.    In order to generate the in vitro conjugated product we use the 
principles of intein chemistry to generate a thioester on SUMO.  We incorporate PCA at 
previously predicted SUMOylation sites and set up a reaction with the SUMO derived thioester.  
We purified the conjugated products and this conjugated product will be utilized to create better 
anti-ischemia agents for patients with strokes or metabolic disorders that require high oxygen 
demands.  
 
 
 
 
 
Introduction: 
 Native chemical ligation (NCL) is one of the most useful techniques for synthesizing a 
native peptide bond between two unprotected proteins or large peptides [1, 2].  The chemistry 
involves a C-terminal thioester reaction with a thiol group on cysteine generating a native bond 
between the two reacting proteins [2].  The overall reaction mechanism of cysteine based NCL is 
shown in Figure (1).   
Figure 1: 
  The thiol group on the N-terminal cysteine on 
protein (P
2
) attacks the carbonyl on the C-
terminal thioester on protein (P
1
) creating a 
covalent bond between both proteins (2).  Then, 
the amine attacks the carbonyl causing an 
intramolecular S to N migration.  This generates 
the final product with proteins 1 and 2 linked 
covalently via a native cysteine residue (3).  
NCL has a wide variety of applications in 
protein engineering including studying post-
translational modifications, peptide cyclization, and peptide construction.  In this present study 
we introduce a genetically encoded pyrrolysine analogue that places a ligation handle directly 
into a recombinant protein that can be used for NCL [3].  Pyrrolysine 1 is the 22
nd
 amino acid 
introduced during translation via a UAG codon [4].  Similarly, D-Cysteine containing 
pyrrolysine analogue (PCA) (S,S)-2 (D-Cys-ε-Lys) has been shown to read through the UAG 
codon with high efficiency [3].  Through NCL this ligation handle in PCA is allowed to react 
with a C-terminal derived thioester generated via intein mediated cleavage by sodium 2-
mercaptoethanesulfonate (MESNa) [5].    
     
 Pyrrolysine 1                PCA    2 
MESNa cleaves specifically between a C-terminal glycine residue on the target protein 
and an N-terminal cysteine residue on intein [5].  When intein is fused to and coexpressed with 
the target protein, a C-terminal thioester can be generated after cleaving with MESNa (Figure 2).  
In this study we use intein chemistry and PCA mediated NCL to ligate Hypoxia Inducible Factor 
-1α (HIF-1α) to Small Ubiquitin like Modifier (SUMO) for future functional analysis.   
Figure 2:   
 
HIF-1α is a transcription factor that is known to generate a protective response during 
hypoxia, a common symptom of stroke in which there are depleted oxygen levels in tissues.   In a 
normoxic state, two conserved proline residues in HIF-1α are hydroxylated by prolyl 
hydroxylase and rapidly targeted for proteasome-mediated degradation through the E3 ubiquitin 
ligase complex which requires the recognition of von Hippel Lindau (VHL) [6-8].  However 
R= CH2CH2SO3Na 
during hypoxia, the hydroxylation of HIF-1α is blocked thereby stabilizing the protein for 
downstream transcription activity.  In a hypoxic response HIF-1α is translocated to the nucleus 
where it dimerizes with constitutively expressed HIF-1β [9].  This dimer is then recognized by 
the coactivators p300/CBD and binds to hypoxia response elements (HREs), promoting the 
transcription of specific genes and eliciting responses such as glycolysis, erythropoiesis, 
angiogenesis and vascular remodeling (Figure 3) [9].   
Figure 3: Adapted from [10] 
             
Furthermore, during hypoxia HIF-1α is conjugated to Small Ubiquitin-like Modifier (SUMO) at 
Lys
391
 and Lys
477
 [12].  SUMO is a small 12 kDa protein that is conjugated to many proteins 
post-translationally via a lysine residue to modify their functions.  However, the role of 
sumoylation in HIF-1α is vaguely understood because HIF-1α is rapidly degraded in normal 
respiring tissues, and Sentrin-specific proteases (SENPs) cleave SUMO away once the function 
of the SUMOylated form is mediated in the cell [11].  Therefore, an in vitro preparation of 
SUMOylated HIF-1α is desired.  To do this we cloned HIF-1α into a vector containing 
pyrrolysine’s tRNA (pylT) and tRNA synthetase (pylS).  We mutate either Lys391 or Lys477 in 
HIF-1α to TAG, so PCA can be incorporated into the protein Figure (4).  We also cloned 
SUMO-Intein-CBD into the PRSF vector Figure (5).   
Figure 4:      Figure 5: 
 
                  
Once SUMO-Intein-CBD is purified and cleaved with MESNa, a thioester on SUMO is 
generated and can react via NCL with PCA labeled HIF-1αGST at the desired SUMOylation 
sites.  This in vitro conjugated product can be employed to study functional analyses in order to 
better understand the role of SUMO on HIF-1α. 
  
Methods:  
HIFGST 
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TAG 
pET-pylST-HIF-1αGST 
plasmid (PET vector) 
 
 
Induction and Purification of His-SUMO-Intein-CBD Fusion Protein 
 The pRSF vector was purchased from Novagen and His-SUMO-Intein-CBD was cloned 
into pRSF by Dr. Manoj Nair. The Histag-SUMO-Intein-CBD plasmid was transformed into BL-
21 competent cells (E. coli) and grown on a kanamycin (kan) resistant LB agar plate at 37 °C for 
approximately 18 hours.  Transformed cells were  inoculated into 500 ml 2xYT bearing a final 
kanamycin concentration of 100 µg/ml and incubated at 37 °C and 250 rpm until the OD600 
reached ~ 0.5.  Isopropyl-β-D-1 thiogalactopyranoside (IPTG) (1mM) was added to the media 
and incubated at 25 ° C overnight at 250 rpm.  The cells were centrifuged for 5 minutes at 4 °C, 
8,000 rpm.  The cells were separated in two 100 ml plastic jars and resuspended in 50 ml 1X 
phosphate buffer (200 mM NaCl, pH 8.0).  Benzamidine- HCl (1 mM) and 
phenylmethylsulfonylfluoride (PMSF) (1 mM) were added to the solution and the cells were 
lysed by sonication.  This solution was centrifuged for 15 minutes at 4 °C, 10,000 rpm and the 
supernatant was filtered using 0.45 µm Ministart filter units.  The protein was purified by affinity 
chromatography by binding to 5 ml nickel resin [Clontech] and incubating for 1 hour at 4 °C.  
The SUMO-Intein-CBD was eluted by using an imidazole gradient (0-1M).  Benzamidine HCl 
was added to each elution to a final concentration of 1 mM.   
Cleavage of His-SUMO-Intein-CBD and Purification of His-SUMO-SR 
Sodium 2-mercaptoethanesulfonate (MESNa) (100 mM) was added to the purified protein 
sample and incubated at room temperature for 48 hours to create a thioester on the C-terminus of 
His-SUMO.  The Intein-CBD was removed by binding to 5 mL chitin beads [BioLabs] and the 
resulting flow through was dialyzed against ligation buffer (10 mM HEPES, 200 mM NaCl, pH 
8.45).  After dialysis, His-SUMO-SR was bound to 5 mL nickel resin [Clontech] by incubating 
for 1 hour at 4 °C.  The protein was eluted using an imidazole gradient (0- 1M).  Benzamidine- 
HCl, MESNa and Tris (2-Carboxyethyl) phosphine Hydrochloride (TCEP) were added to each 
elution in a final concentration of 1 mM for storage.   
Induction and Purification of pETpylST-HIF-1αGST Mutants K391x and K477x 
 The pET vector was purchased from Novagen and pylST was cloned into the vector by 
Dr. Marianne Lee.  HIF-1αGST was cloned into the pET-pylST plasmid by Dr. Manoj Nair.  
HIF-1αGST was mutated at K391x or K477x to TAG. The induction and purification of K391x 
and K477x were performed separately but their procedures were identical.  The pET-pylST-HIF-
1αGST (K391x or K477x) plasmid was transformed into BL-21 competent cells (E.coli) and 
incubated on two ampicillin bearing agar plates at 37 °C for approximately 18 hours.  
Transformed cells were inoculated into 100ml 2XYT media bearing 100 µg/ml of ampicillin and 
incubated at 37 °C and 250 rpm until the OD600 reached 0.6.  PCA (synthesized by Dr. Tomek 
Fekner) was added to the media at a final concentration of 5mM and the pH of media was 
restored to ~7.5 using 1M Tris base.  IPTG (1 mM) was added to all four flasks and then 
incubated at 25 °C with shaking at 250 rpm overnight.  The cells were centrifuged in a 50 ml 
falcon tube (1 falcon tube/ flask) at 8,000 x g at 4 °C for 10 minutes.  The resulting pellets were 
resuspended in 25 mL HEPES buffer (10 mM HEPES, 0.5 M NaCL, 1 mM TCEP, 1 mM 
benzamidine - HCl pH 8.0) and lysed by sonication.  The remaining cells were centrifuged at 
10,000 rpm for 10 minutes and the supernatant was bound to GST resin by incubating for 1 hour 
at 4 °C.  The column was washed by incubating with 4 mL GST wash buffer (30 mM 
glutathione, 200 mM NaCl, 10 mM HEPES, 1 mM TCEP, 1 mM benzamidine- HCl) for 5 
minutes at 4 °C.  The protein was eluted by incubating with 3 mL GST elution buffer (100 mM 
glutathione, 200 mM NaCl, 10 mM HEPES, 1 mM TCEP, 1 mM benzamidine- HCl) for 15 
minutes at 4 °C.  This step was repeated until no blue color was shown on a Bradford analysis.     
Benzamidine HCl and TCEP were added to each elution at a final concentration of 1 mM for 
storage.   
Ligation of His-SUMO-SR to HIFGST Mutants K391x and K477x and purification of 
SUMOylated Products: 
Mutants K391x and K477x share the same procedure but were prepared separately.  The HIF-
1αGST 100 mM elutions were concentrated using a 30K cutoff centrifugal filter unit [Millipore] 
and dialyzed against ligation buffer (10 mM HEPES, 200 mM NaCl, pH 8.45).  His-SUMO-SR 
was concentrated using a 3K cutoff [Millipore] and dialyzed against ligation buffer.  The 
concentrations were measured using a Bradford analysis and SUMO-SR was added to the 100 
mM concentrated sample based on a 2:1 mass ratio SUMO: HIF.  Benzamidine –HCl was added 
in a final concentration of 2 mM.  The tube was incubated at room temperature with moderate 
mixing for 36 hours.  GST resin (200 µl) was washed with 10 -X CV of water and then 10-X CV 
of ligation buffer.  The ligation sample was added to the resin and incubated at 4 °C for 2 hours.  
The resin- protein mixture was placed into a spin column and centrifuged for 1 minute at 1000 x 
g.  After washing the resin with ligation buffer, GST elution buffer (100 mM glutathione, 200 µl) 
was added to the spin column and incubated at 4 °C for 30 minutes.  The eluate was collected by 
centrifugation at 1000 x g for 1 minute.  This process of incubating with GST elution buffer was 
repeated until no blue color was seen using a Bradford analysis.  Nickel resin (200 µl) was 
washed with 10 -X CV of water and then 10-X CV of ligation buffer.  The elutions from the GST 
resin were pooled and incubated with the nickel resin at 4 °C for 2 hours.  The resin protein 
mixture was placed into a spin column and centrifuged for 1 minute at 1000 x g.  The pure 
ligated product was eluted by incubating for 15 minutes with increasing concentrations of 
imidazole (0- 1M) in a stepwise fashion.  The elutions were collected by centrifugation for 1 
minute at 1000 x g. 
Results: 
Generation of Thioester on SUMO 
In order to SUMOylate HIF-1α in vitro we must first generate a thioester on SUMO.  Our 
plasmid contains the SUMO-Intein fusion protein with a C-terminal Histag on SUMO and an N-
terminal chitin-binding domain (CBD) on Intein.  First, we purify the Histag-SUMO-Intein-CBD 
via affinity chromatography by binding to nickel resin.  The bulk of the protein eluted at 200 mM 
and 500 mM imidazole as shown on Figure (6).  The purified SUMO-Intein was cleaved with 
MESNa and most of the Intein-CBD and full length protein were removed by binding to chitin 
beads Figure (7). The presence of of Intein-CBD and full length protein indicate that the binding 
to chitin was insufficient however, the washes are much cleaner.  We pooled washes 1 and 2 
from Figure (7) and we purified via affinity chromatography by binding to nickel resin.  Once 
again, the resulting protein was eluted at 200 mM and 500 mM imidazole Figure (8).  It may also 
be noted that 1 mM MESNa and 1 mM TCEP were added for storage to prevent SUMO-SR 
oxidation.    
 
 
 
 
 
Figure 6:       Figure 7: 
     
  
Figure 8: 
         
 
Purification of HIFGST K391x and K477x 
Figure (6) shows the SDS-PAGE of the SUMO-Intein 
purification.  The bulk of our protein eluted at 200 mM 
and 500 mM imidazole.    
Figure (7) shows the SDS-PAGE after 
cleavage with MESNa.  Most of the Intein-
CBD and full length protein was removed 
by binding to chitin beads.   
Figure (8) shows the SDS-PAGE of the SUMO-SR.  Our protein eluted at 200 
mM and 500 mM imidazole as one solid band.    
 
We purified both mutants separately, but the procedure was identical.  The mutants were purified 
via affinity chromatography and eluted using 30 mM and 100 mM glutathione.  Some of our 
protein eluted at 30 mM glutathione, but it was contaminated with other proteins.  Then, both 
mutants were eluted using 100 mM glutathione for cleaner results.  The SDS-PAGE of mutants 
K391x and K477x are shown in figures (9) and (10) respectively and are running at ~ 60 kDa in 
size.  To confirm the identity of the mutants we performed a Western Blot using an anti-GST 
antibody Figure (11).  The result shows purified HIF-1αGST K391x and K477x around the 
approximate size shown on the SDS-PAGE.     
Figure 9:   
  
 
 
Figure (9) is an 
SDS-PAGE of 
HIF-1αGST 
mutant K391X.  
Some of our 
protein eluted at 
30 mM 
glutathione but 
was dirty.  After 
most of the 
impurities were 
washed away 
with 30 mM 
glutathione our 
pure protein was 
eluted with 100 
mM glutathione.  
HIF-1αGST was 
running at ~ 60 
kDa.   
Figure 10:  
 
 
Figure 11: 
 
 
       
 
Figure (10) is 
an SDS-PAGE 
of HIF-1αGST 
mutant K477X.  
Some of our 
protein eluted 
at 30 mM 
glutathione but 
was dirty.  
After most of 
the impurities 
were washed 
away with 30 
mM 
glutathione our 
pure protein 
was eluted with 
100 mM 
glutathione.  
HIF-1αGST 
K477x was 
running at ~ 60 
kDa.   
Figure (11) shows a 
Western blot of 
purified K391 and 
K477.  The antibody 
used here was an anti-
GST antibody.  There 
appears to be mild 
degradation of mutant 
K391. 
Purified HIFGST 
K477 
Purified HIFGST 
K391 
Purification of Ligated Products K391 and K477 
 The K391x and K477x mutants were purified separately but by the same procedure.  
Mutants K391x and K477x were first purified via GST affinity chromatography.  Figure (12) 
shows the SDS-PAGE of K391x after GST purification and figure (14) shows the SDS-PAGE of 
K477x after GST purification.  All of the SUMO-SR that did not react with HIF-1α did not bind 
and is seen in the flow through in both of these figures.  Next, the elutions were pooled and 
purified via nickel resin.    Figure (13) shows the SDS-PAGE of K391x after Histag purification 
and figure (15) shows the SDS-PAGE of K477x after Histag purification.  The ligated product 
runs at ~ 75 kDa.  To confirm that this 75 kDa band corresponds to the ligated product we 
performed a Western blot using anti-SUMO and anti-HIF antibodies.  We did not have enough 
ligated K477x protein left after purification to do a clean western blot, but we did have enough to 
test one for ligated K391x.  Figure (16) is an anti-SUMO Western blot of pure ligated K391x.  
Figure (17) is an anti-HIF Western blot of ligated K391x before purification.  I am in the process 
of creating an anti-HIF Western of pure ligated K391x.    
 
 
 
 
 
 
 
Purification of K391 Ligated product 
Figure 12: 
 
  
Figure 13: 
 
 
 
 
 
Figure (12) shows the SDS-PAGE of ligation purification of 
K391x after GST purification. 
~ 75 kDa 
Figure (13) is an SDS-PAGE of ligated K391x after nickel purification. The protein eluted 
at all concentrations of imidazole.  The ligated K391x product runs at ~ 75 kDa.  
 
  
 
Purification of K477 Ligated Product 
 
Figure 14: 
          
 
 
 
Figure 15: 
         
 
Figure (14) shows the SDS-PAGE of ligation purification of 
K477x after GST purification. 
~ 75 kDa 
Figure (15) is an SDS-PAGE of ligated K477x after nickel purification. The protein eluted 
at all concentrations of imidazole.  The ligated K477x product runs at ~ 75 kDa.  
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Discussion:  
 Although NCL is widely used in connecting two proteins via a cysteine residue, the uses 
of NCL have been limited to a thioester reaction with an N-terminal cysteine [13-15].  This 
hinders the ability to utilize NCL site specifically because the reaction is restricted to a C to N-
terminus ligation.  Herein we deviate from the usual method of NCL by utilizing our pyrrolysine 
analog PCA.  This allows us to site specifically incorporate PCA into a protein which can then 
react with a C-terminal thioester by NCL.  This greatly increases the uses of NCL because we 
now have multiple potential positions that can undergo NCL, and we are not limited to an N-
~75 kDa ~75 kDa 
Figure (16) is an anti-SUMO Western blot of pure ligated K391x and Figure (17) is an 
anti-HIF Western blot of ligated K391x before purification.   
terminal cysteine.  Therefore, any post-translational modification in which another protein or 
small molecule is attached via a lysine residue can be studied using PCA mediated NCL.  These 
include sumoylation, ubiquitination, biotinylation, succinylation and many more.  To investigate 
uses of PCA mediated NCL, we synthesized SUMOylated HIF-1α. 
The first step in elucidating the function of SUMO on HIF-1α is an in vitro synthesis of 
SUMOylated HIF-1α.  As I mentioned earlier, the role of sumoylation in HIF-1α is vaguely 
understood because HIF-1α is rapidly degraded in normal respiring tissues, and SENPs cleave 
SUMO away once the function of the SUMOylated form is mediated in the cell [11].  This 
hinders the ability to study the effect of SUMO on HIF-1α in vivo.  However, with PCA 
mediated NCL we have successfully created the in vitro conjugated products at the two 
sumoylation sites.  The increase from a 60 kDa band in the HIF-1αGST purifications to a 75 kDa 
band in the SUMOylated HIF-1αGST purifications signifies that SUMO, which is running at 17 
kDa, is ligated to HIFGST in both mutants.  The Western blot of K391x also confirms the 
presence of the ligated product because it reacted with the anti-SUMO and anti-HIF antibodies.   
Now that we have a stable conjugated product we can begin to identify the role 
sumoylation plays in HIF-1α.  There are multiple potential functions SUMO could have during 
hypoxia.  SUMO could block the function of prolyl hydroxylase, leading to HIF-1α stabilization 
and downstream transcription activity.  Moreover, SUMO could aid in the translocation of HIF-
1α to the nucleus, or assist in DNA binding.  SUMO could have one or more of these functions 
and to fully understand SUMO’s role during hypoxia all of these potential functions must be 
tested.  Furthermore, it is possible that both K391x and K477x sites need to be SUMOylated in 
order to carry out its function(s) during hypoxia.  We have a plasmid with HIF-1αGST mutated 
at sites K391x and K477x, and we have tested the expression (data not shown).  However, we 
need to purify the double mutant and set up a ligation reaction with SUMO.  With the availability 
of the various forms of HIF1α (conjugated to PCA at one or multiple sites), we plan to probe the 
role of this post translation modification in the mechanism of action of HIF1α.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Works Cited 
1. P. E. Dawson, T. W. Muir, I. Clark-Lewis, S. B. Kent. Synthesis of proteins by native 
chemical ligation. Science. 1994, 266, 776–779. 
2. S. B. Kent.  Total chemical synthesis of proteins. Chem. Soc. Rev. 2009, 38, 338–351. 
3. Li X, Fekner T, Ottesen JJ, and Chan MK. A pyrrolysine analogue for site-specific protein 
ubiquitination. Angew Chem Int Ed Engl. 2009;48(48):9184-7. 
4. Fekner T, and Chan MK. The pyrrolysine translational machinery as a genetic-code expansion 
tool. Curr Opin Chem Biol. 2011 Apr 19. 
5. Chattopadhaya S, Abu Bakar FB, and Yao SQ. Use of intein-mediated protein ligation 
strategies for the fabrication of functional protein arrays. Methods Enzymol. 2009;462:195-223. 
6.  Bruick RK, McKnight SL. A conserved family of prolyl-4-hydroxylases that modify HIF. 
Science. 2001;294:1337–1340.  
7.  Maxwell PH, Wiesener MS, Chang GW, Clifford SC, Vaux EC, et al. The tumour suppressor 
protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature. 
1999;399:271–275. 
8.  Ohh M, Park CW, Ivan M, Hoffman MA, Kim TY, et al. Ubiquitination of hypoxia-inducible 
factor requires direct binding to the beta-domain of the von Hippel-Lindau protein. Nat Cell Biol. 
2000;2:423. 
9.  Semenza GL. HIF-1 and mechanisms of hypoxia sensing. Curr Opin Cell Biol. 2001;13:167–
171. 
10. Carroll V, and Ashcroft M. HIF-1α regulation by proline hydroxylation.  Expert Reviews in 
Molecular Medicine. Cambridge University. 2005; 7(6): 1 
11. Cheng J, Kang X, Zhang S, Yeh ET. SUMO-specific protease 1 is essential for stabilization 
of HIF1alpha during hypoxia. Cell Press. 2007 Nov 2;131(3):584-95. 
12. Bae SH, Jeong JW, Park JA, Kim SH, Bae MK, Choi SJ, and Kim KW. Sumoylation 
increases HIF-1α stability and its transcriptional activity. Biochem Biophys Res Commun. 2004 
Nov 5;324(1):394-400. 
 13. Rohde H, Schmalisch J, Harpaz Z, Diezmann F, and Seitz O. Ascorbate as an Alternative to 
Thiol Additives in Native Chemical Ligation. Chembiochem. 2011 May 6. doi: 
10.1002/cbic.201100179. 
14. Mende F, Beisswenger M, and Seitz O. Automated Fmoc-based solid-phase synthesis of 
peptide thioesters with self-purification effect and application in the construction of immobilized 
SH3 domains. J Am Chem Soc. 2010 Aug 18;132(32):11110-8. 
15. Shang S, Tan Z, and Danishefsky SJ. Application of the logic of cysteine-free native 
chemical ligation to the synthesis of Human Parathyroid Hormone (hPTH). Proc Natl Acad Sci 
U S A. 2011 Apr 12;108(15):5986-9. Epub 2011 Mar 28. 
 
 
 
 
 
 
 
 
 
